Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

The authors observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor olaparib.